Radiation therapy cuts prostate cancer death: study

WASHINGTON (Reuters) - Adding radiation therapy to standard drug treatment can cut in half the death rate from advanced prostate cancer and should become the standard of care globally, Swedish researchers reported on Monday.

Their study of more than 800 prostate cancer patients showed that nearly 24 percent of men who got only standard drugs had died after 10 years, compared with just under 12 percent of men who also got radiation treatment.

Adding radiation does not add too many side-effects, they wrote in the journal Lancet Oncology.

“The quality of life and adverse effect profile is acceptable. We therefore suggest that endocrine treatment plus radiotherapy should be the new standard of care for these patients,” Anders Widmark of Umea University in Sweden and colleagues wrote.

“The results should change current practice, making long-term hormonal therapy plus radical radiotherapy the standard of care for men with locally advanced prostate cancer,” Dr. Chris Parker and Dr. Alex Tan of Britain’s Institute of Cancer Research in Sutton, Surrey, wrote in a commentary.

Prostate cancer is the second-leading cancer killer of men, killing 221,000 every year globally, with 679,000 new cases diagnosed.

It is easily cured in early stages with surgery or radiation. For prostate cancer that has spread, drugs that interfere with cancer-fueling hormones are prescribed.

In the United States, adding radiation therapy is already standard, said Dr. Howard Sandler, chair of Radiation Oncology at Cedars-Sinai Medical Center in Los Angeles and a spokesman for the American Society of Clinical Oncology.

He said health agencies in Europe did not always provide radiation as the standard of care. “A 50 percent reduction in the risk of prostate cancer death is a real clinical benefit,” Sandler said in a telephone interview.

“The radiation therapy that was performed here (in the study) was somewhat simplistic,” Sandler added. “Modern radiation therapy with higher doses, if anything, might magnify the benefits.”

(Reporting by Maggie Fox; Editing by Will Dunham and Peter Cooney)


Related Posts:

NEW YORK (Reuters Health) - The results of small study suggest that radiotherapy can be safely used to treat prostate cancer in HIV-infected men. Treatment appears to have no long-term effect on CD4+ cell count or viral load. When considering radiotherapy for prostate cancer, there is no reason that HIV-infected patients should be treated differently than

Full Post: Prostate cancer radiotherapy safe for HIV patients

NEW YORK (Reuters Health) - Drugs used to control diabetes may lower the risk of prostate cancer, investigators at the University of Tampere in Finland report. “Recent studies have reported a decreased prostate cancer risk for diabetic men, although the evidence is controversial,” Dr. Teemu J. Murtola and colleagues note in the American Journal of Epidemiology.

Full Post: Diabetes drugs tied to lower prostate cancer risk

NEW YORK (Reuters Health) - In patients with advanced chronic hepatitis C infection who have not responded to prior therapy with the standard combination drug treatment — peginterferon and ribavirin — prolonged low-dose, or “maintenance” therapy does not reduce the rate of disease progression, new research shows. Patients who do not respond to initial antiviral therapy

Full Post: No benefit of extended hepatitis C therapy for some

NEW YORK (Reuters Health) - Surgical removal of the kidney — a procedure known as nephrectomy — improves survival in patients with locally advanced renal cell carcinoma, the most common form of kidney cancer. Dr. Pierre I. Karakiewicz from University of Montreal and colleagues determined survival rates for 43,143 patients treated with nephrectomy for advanced renal

Full Post: Surgery improves kidney cancer survival: study

NEW YORK (Reuters Health) - Noscapine, a natural substance found in cough medicine, may prove useful in treating advanced prostate cancer, according to studies in mice. Researchers found that noscapine — a non-addictive derivative of opium — reduced tumor growth in mice by 60 percent and limited the spread of tumors by 65 percent without causing

Full Post: Cough medicine ingredient may treat prostate cancer

Site Navigation

Most Read



  • kinwrite.com@gmail.com